C-W1OIJocasta Neuroscience
Klotho protein, cognitive health, neurodegeneration
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-W1OI
C-W1OIC-W1OIKlotho protein, cognitive health, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Jocasta Neuroscience Klotho protein, cognitive health, neurodegeneration
Jocasta Neuroscience is focused on the therapeutic potential of Klotho for improving how people age cognitively. Its proprietary synthetic subcutaneous formulation, JN-0413, is described as a first-in-class and best-in-class treatment. The company says human trials are estimated to begin in 2026, pending ongoing manufacturing.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Jocasta Neuroscience — Early mechanism · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic